22.26
-0.89
(-3.84%)
May 21 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 22.13 - 23.23 |
| 52 week | 15.43 - 26.30 |
| Open | 23.15 |
| Vol / Avg. | 0.00/956,346.00 |
| Mkt cap | 3.02B |
| P/E | - |
| Div/yield | - |
| EPS | -0.12 |
| Shares | 135.75M |
| Beta | 2.17 |
| Inst. own | 113% |
Events
Jul 29, 2013
Q2 2013 Incyte Corporation Earnings Release
May 20, 2013
Incyte Corporation at UBS Global Healthcare Conference -
May 15, 2013
Incyte Corporation at Bank of America Merrill Lynch Health Care Conference -
May 2, 2013
Q1 2013 Incyte Corporation Earnings Conference Call -
May 2, 2013
Q1 2013 Incyte Corporation Earnings Release
Mar 13, 2013
Incyte Corporation at Barclays Healthcare Conference -
Mar 6, 2013
Incyte Corporation at Cowen Health Care Conference -
Feb 25, 2013
Incyte Corporation at Canaccord Genuity Orphan Drug Day
Feb 25, 2013
Incyte Corporation at Canaccord Genuity Orphan Drug Day
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -22.05% | -14.92% |
| Operating margin | -5.76% | 0.39% |
| EBITD margin | - | 10.48% |
| Return on average assets | -19.02% | -13.44% |
| Return on average equity | - | - |
| Employees | 413 | - |
| Carbon Disclosure Rating | - | - |
Address
Experimetal Station Route 141 & Henry Clay Rd. Building E336
WILMINGTON, DE 19880
United States - Map
+1-302-4986700 (Phone)
+1-302-6365454 (Fax)
WILMINGTON, DE 19880
United States - Map
+1-302-4986700 (Phone)
+1-302-6365454 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. Its advanced compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received worldwide development and commercialization rights for the compound for inflammatory and autoimmune diseases. In November 2011, JAKAFI became commercially available in the United States and is being marketed in the United States.
Officers and directors
| Richard U. De Schutter | Independent Chairman of the Board | |
| Paul A. Friedman M.D. | President, Chief Executive Officer, Director | |
| David C. Hastings | Chief Financial Officer, Executive Vice President | |
| Eric H. Siegel | Executive Vice President, General Counsel | |
| Paula J. Swain | Executive Vice President - Human Resources | |
| James M. Daly | Executive Vice President, Chief Commercial Officer | |
| Richard S. Levy M.D. | Executive Vice President, Chief Drug Development and Medical Officer | |
| Roy A. Whitfield | Director | |
| Barry Michael Ariko | Independent Director | |
| Julian C. Baker | Independent Director |